BAM Logo

TP53 Deletions at 17p13.1 in CLL (FISH)

EPTIS factsheet 794305 | Last revision 2020-10-23 | URL: https://www.eptis.bam.de/pts794305 https://www.eptis.bam.de/pts794305

PT provider
Based in Australia
Language(s) English
Remarks In collaboration with Australasian Society of Diagnostic Genomics (ASDG), this module qualitatively assesses laboratory performance in the detection of TP53 deletions at 17p13.1 in chronic lymphocytic leukaemia (CLL) using fluorescence in-situ hybridisation (FISH).
Product groups Human test material
Testing fields Medical analysis
Technical details
Test item Tested property Testing method
Interphase nuclei (bone marrow) TP53 deletion in 17p13.1 Molecular genetic testing
Cytogenetic testing
Aims of the PT scheme
Target group of participants
Linked to specific legislation / standards
Additional, subsidiary aims
Number of participants
Accredited or otherwise reviewed by a 3rd party
Operation is commissioned / requested by
Fees and frequency
Participation fee Yes
Regularly operated Yes (3 cases per survey/1 surveys)
Year of first operation
Contact details of the PT provider
Provider Contact person
Suite 201/8 Herbert Street
St Leonards, 2065

Phone: (61 2) 9045 6000
Fax: (61 2) 9356 2003
Web: https://www.rcpaqap.com.au/ https://www.rcpaqap.com.au/
Mr Rhys Judd
Phone: (61 2) 9045 6000
Fax: (61 2) 9356 2003
Email: rhys.judd@rcpaqap.com.au rhys.judd@rcpaqap.com.au
If you find any mistakes please contact the responsible EPTIS coordinator in Australia, Ms Luminita Antin. Ms Luminita Antin.
Any questions or problems? Please contact us at eptis@bam.de.
Application version: 1.23-SNAPSHOT.20230502124635-7925ae379a631fc1ececff45d2921c8db38877d5